We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Encompass Health (EHC - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Encompass Health is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Encompass Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for EHC's full-year earnings has moved 4.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, EHC has gained about 30.7% so far this year. At the same time, Medical stocks have lost an average of 4.2%. This means that Encompass Health is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is EUROFINS SCIENT (ERFSF - Free Report) . The stock is up 32.7% year-to-date.
For EUROFINS SCIENT, the consensus EPS estimate for the current year has increased 8.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Encompass Health belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #37 in the Zacks Industry Rank. On average, stocks in this group have gained 4.8% this year, meaning that EHC is performing better in terms of year-to-date returns.
On the other hand, EUROFINS SCIENT belongs to the Medical Services industry. This 58-stock industry is currently ranked #67. The industry has moved -0.6% year to date.
Investors interested in the Medical sector may want to keep a close eye on Encompass Health and EUROFINS SCIENT as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Encompass Health (EHC - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Encompass Health is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Encompass Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for EHC's full-year earnings has moved 4.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, EHC has gained about 30.7% so far this year. At the same time, Medical stocks have lost an average of 4.2%. This means that Encompass Health is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is EUROFINS SCIENT (ERFSF - Free Report) . The stock is up 32.7% year-to-date.
For EUROFINS SCIENT, the consensus EPS estimate for the current year has increased 8.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Encompass Health belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #37 in the Zacks Industry Rank. On average, stocks in this group have gained 4.8% this year, meaning that EHC is performing better in terms of year-to-date returns.
On the other hand, EUROFINS SCIENT belongs to the Medical Services industry. This 58-stock industry is currently ranked #67. The industry has moved -0.6% year to date.
Investors interested in the Medical sector may want to keep a close eye on Encompass Health and EUROFINS SCIENT as they attempt to continue their solid performance.